0000899243-22-031602.txt : 20220920
0000899243-22-031602.hdr.sgml : 20220920
20220920174724
ACCESSION NUMBER: 0000899243-22-031602
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220916
FILED AS OF DATE: 20220920
DATE AS OF CHANGE: 20220920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Canaan XI L.P.
CENTRAL INDEX KEY: 0001712417
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 221254620
BUSINESS ADDRESS:
STREET 1: 285 RIVERSIDE AVENUE
STREET 2: SUITE 250
CITY: WESTPORT
STATE: CT
ZIP: 06880
BUSINESS PHONE: 203-855-0400
MAIL ADDRESS:
STREET 1: 285 RIVERSIDE AVENUE
STREET 2: SUITE 250
CITY: WESTPORT
STATE: CT
ZIP: 06880
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Canaan Partners XI LLC
CENTRAL INDEX KEY: 0001850694
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 221254619
BUSINESS ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 203-855-0400
MAIL ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
BUSINESS PHONE: 206-913-4300
MAIL ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-16
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001712417
Canaan XI L.P.
285 RIVERSIDE AVENUE, SUITE 250
WESTPORT
CT
06880
0
0
1
0
0001850694
Canaan Partners XI LLC
285 RIVERSIDE AVENUE, SUITE 250
WESTPORT
CT
06880
0
0
1
0
Common Stock
2022-09-16
4
S
0
111585
21.53
D
9307021
D
Common Stock
2022-09-16
4
S
0
3722
22.04
D
9303299
D
Common Stock
2022-09-19
4
S
0
76725
20.57
D
9226574
D
Common Stock
2022-09-20
4
S
0
146404
19.50
D
9080170
D
Common Stock
2022-09-20
4
S
0
2266
20.10
D
9077904
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Canaan XI L.P., By: Canaan Partners XI LLC, its general partner, By: /s/ Nancy Levenson, Attorney-in-Fact
2022-09-20
Canaan Partners XI LLC, By: /s/ Nancy Levenson, Attorney-in-Fact
2022-09-20